Compounding

02
Sep

Compounding to Get More Scrutiny?

I read two articles today that made me wonder what the next year will look like for enforcement activity in the compounding arena. First was an article by Peter Pitts published in RealClear Health (here) titled “The Compounding Loophole Has Become a Business Model”. The second is a report in the Pink Sheet written by […]

Read More
31
Aug

Draft Guidance for Industry – GFI #256B – Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities

For those of us in the Animal Drug world, we know it is unusual to hear much regarding compounding of animal drugs. Generally speaking, Animal Drug Compounding is prohibited; in accordance with GFI #256, “animal drugs compounded from bulk drug substances by pharmacists and veterinarians do not meet certain important requirements of the Federal Food, […]

Read More
27
Aug

Pharmacy Compounder Problem with Use of Dietary Grade Glutathione

In an article published today on FDA’s webpage (here), the FDA notes that it “is aware of reports of at least 30 patients who experienced adverse events following the administration of intravenous (IV) glutathione alone or in combination with other ingredients”. The problem has been identified as the use of a dietary grade of glutathione […]

Read More
30
Jul

503B Outsourcing Facility Fee Rates for FY 2027

FDA has announced the Outsourcing Facility Fee rates (here) for registered compounding facilities and their reinspection. The fees are broken down into qualified Small Business Establishment which pay a reduced fee, and Non-Small Business Establishment fees which pay a full fee. If there are any issues uncovered during an inspection of an outsourcing facility, and […]

Read More
17
Jul

Get Your Reading Glasses On – CDER Guidance Plans for 2026 Cite 85 Documents

With four and a half months remaining in fiscal year 2026, the Center for Drug Evaluation and Research (CDER) has published the list of 85 new or revised guidance documents that it plans to release this year! The document (here) categories along with the number of anticipated guidances are as follows: Administrative/Procedural – 8 Artificial […]

Read More
08
Jul

HHS Unified Rule Agenda for 2026

The list is long (here) and there are some interesting regulatory items found in the agenda for FDA. Take some time and peruse them all as I will just highlight a few items of interest in this post. Here are some of the proposed rules that caught my attention: Current Good Manufacturing Practice for Outsourcing […]

Read More
07
Jul
D-Day Coming for the Use of Certain Peptides in Pharmacy Compounding

D-Day Coming for the Use of Certain Peptides in Pharmacy Compounding

In a previous blog posted on April 16, 2026 (here), we discussed the announcement from FDA regarding an upcoming meeting of the Pharmacy Compounding Advisory Committee to be held on July 23-24, 2026, focused on the inclusion of some active ingredients on the permitted pharmacy compounding list. That post identified seven peptide active ingredients that […]

Read More
01
May

Preliminary Decision to Exclude Certain GLP-1 Drugs From the 503B Bulks List

Today, the FDA published a Federal Register (FR) notice (here) announcing a preliminary decision regarding three bulk drug substances that it “has evaluated and is proposing not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide.” The notice further states that the FDA will consider comments submitted to the docket until June 30, 2026 […]

Read More
1 2 … 8